Pharmacy and Medically Underserved Areas Enhancement Act

H.R. 2759/S. 1362 -- the Pharmacy and Medically Underserved Areas Enhancement Act, legislation to recognize pharmacists and their services in Medicare Part B. H.R. 7213 -- This bill expands Medicare coverage to permanently include services provided by a pharmacist, including incidental services and supplies, related to testing, drug regimens, and vaccines for COVID-19, influenza, and certain other illnesses.

Client expense: $35,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 2759/S. 1362 -- the Pharmacy and Medically Underserved Areas Enhancement Act, legislation to recognize pharmacists and their services in Medicare Part B. H.R. 7213 -- This bill expands Medicare coverage to permanently include services provided by a pharmacist, including incidental services and supplies, related to testing, drug regimens, and vaccines for COVID-19, influenza, and certain other illnesses.

Client expense: $35,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Pre-approval information exchange - lobbying for the introduction of a bill to codify FDA guidance creating a safe harbor for the practice of pre-approval information exchange between drug manufacturers and health plans. HR 7008/HR 7667/HR 9297/HR 2617 S.1909/HR. 3554 - A bill relating to direct and indirect remuneration in Medicare Part D. S. 1362 - Pharmacy and Medically Underserved Areas Enhancement Act - to provide for coverage under the Medicare program of pharmacist services S. 3791/HR 7051 - Access to Prescription Digital Therapeutics Act of 2022 - to create a benefit category in Medicare and Medicaid for prescription digital therapeutics HR 7213 - Equitable Community Access to Pharmacy Services Act of 2022 - to reimburse certain COVID-19 care services provided by pharmacists under Medicare Part B

Client expense: $90,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Pre-approval information exchange - lobbying for the introduction of a bill to codify FDA guidance creating a safe harbor for the practice of pre-approval information exchange between drug manufacturers and health plans. HR 7008/HR 7667/HR 9297/HR 2617 S.1909/HR. 3554 - A bill relating to direct and indirect remuneration in Medicare Part D. S. 1362 - Pharmacy and Medically Underserved Areas Enhancement Act - to provide for coverage under the Medicare program of pharmacist services S. 3791/HR 7051 - Access to Prescription Digital Therapeutics Act of 2022 - to create a benefit category in Medicare and Medicaid for prescription digital therapeutics HR 7213 - Equitable Community Access to Pharmacy Services Act of 2022 - to reimburse certain COVID-19 care services provided by pharmacists under Medicare Part B

Client expense: $90,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

The Pharmacist and Medically Underserved Areas Enhancement Act (H.R. 2759/S. 1362) and the Equitable Community Access to Pharmacist Services Act (H.R. 7213), provisions related to Medicare coverage for all PREP Act services and COVID-19 response recommendations, including Medicaid reimbursement for pharmacist provision of testing and vaccination. Issues related to telehealth reimbursement and virtual supervision flexibilities for pharmacist services with CMS (generally, no specific legislation). Issues related to continuation of Public Readiness and Emergency Preparedness Act (PREP Act) allowances (generally, no specific legislation).

Client expense: $270,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Issues pertaining to pharmacists' services including S 1362, Pharmacy and Medically Underserved Areas Enhancement Act and HR 7213, Equitable Community Access to Pharmacists Services Issues relating to the pharmaceutical supply chain, including HR 2870, Essential Medicines Strategic Stockpile Act Drug pricing legislation, including S 1388

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 3554 / S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act; H.R. 2608, the Ensuring Seniors Access to Local Pharmacies Act; H.R. 2759 / S. 1362, the Pharmacy and Medically Underserved Areas Enhancement Act; H.R. 3682, the Improving Transparency to Lower Drug Costs Act; H.R. 2484, the Lowest Price for Patients Act; H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R. 19 / S. 2164, the Lower Costs, More Cures Act of 2021; H.R. 3173, the Improving Seniors Timely Access to Care Act of 2021; H.R. 4121, the PRO Seniors Act; Proposed inclusion of Medicaid managed care spread pricing prohibition to pay for H.R. 3684, the Infrastructure Investment and Jobs Act; H.R. 5237, the Reduced Costs and Continued Cures Act of 2021 H.R. 5376, the Build Back Better Act; H.R. 5804, the Expanding Access to Diabetes Self-Management Training Act of 2021; H.R. 6101, the Drug Price Transparency in Medicaid Act of 2021; Part B billing and COVID oral antivirals; S. 3700, the Affordable Insulin Now Act; H.R. 7213, Equitable Community Access to Pharmacist Services Act; CY 2023 Medicare Advantage and Part D Final Rule (CMS-4192-F); Draft legislation, the Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act; H.R. 5376, the Inflation Reduction Act of 2022; Draft legislation on pharmacy DIR fee reform

Client expense: $320,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Small Business Administration (SBA), White House Office

Drug Pricing HR 5376, Build Back Better Act HR 4385/S 3080, the Cancer Drug Parity Act HR 2759/S 1362, the Pharmacy and Medically Underserved Areas Enhancement Act HR 7213, the Equitable Community Access to Pharmacists Services Act Cancer Moonshot

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office

IPC supports The Pharmacy Benefit Manager Transparency Act of 2022 IPC supports S. 1909/H.R. 3554, the Pharmacy DIR Reform to Reduce Senior Drug Costs Act. Support regulations/laws that would eliminate pharmacy DIR. Medicare Program; Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs(CMS-4192-P). Support with amendments. IPC supports Pharmacists as Providers under Medicare Part B. IPC supports Pharmacy and Medically Underserved Areas Enhancement Act, H.R. 2759/S. 1362 IPC supports Pharmacists as Immunizers IPC supports 340B Program and contract pharmacies IPC supports Federal Retail Pharmacy COVID-19 Vaccination Program expansion. IPC supports MCO Medicaid reform and elimination of spread pricing IPC supports FTC investigation into vertical PBM arrangements IPC is against decreased pharmacy reimbursement in the TRICARE program IPC is neutral and sought clarifications on the drug pricing provisions of the Inflation Reduction Act of 2022.

Client expense: $30,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE, White House Office

Communicate with the Center for Medicare and Medicaid Services regarding direct reimbursement under Medicare Program, annual payment updates, PBM transparency, and scope of practice. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect remuneration fees (DIR) under Medicare Part D and Medicare rebate reform. Communication with CMS, White House Offices, and Congressional Offices on Reimbursement through Medicare Part B. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House and Senate Offices, and HHS. Discussed telehealth reimbursement and virtual supervision flexibilities for pharmacist services with CMS. Discussed continuation of PREP Act allowances with HHS. Discussion with House and Senate Offices about the Pharmacist and Medically Underserved Areas Enhancement Act (H.R. 2759/S. 1362) and The Equitable Community Access to Pharmacist Services Act (H.R. 7213).

Client expense: $355,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Requested that CMS mandate state Medicaid programs to cover all PREP Act services (i.e., vaccination, testing, and treatment). Communication with the Center for Medicare and Medicaid Services regarding direct reimbursement under Medicare Program, annual payment updates, PBM transparency, and scope of practice. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect remuneration fees (DIR) under Medicare Part D and Medicare rebate reform. Communication with CMS, White House Offices, and Congressional Offices on Reimbursement through Medicare Part B. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House and Senate Offices, and HHS. Discussed telehealth reimbursement and virtual supervision flexibilities for pharmacist services with CMS. Discussed continuation of PREP Act allowances with HHS. Discussion with House and Senate Offices about the Pharmacist and Medically Underserved Areas Enhancement Act (H.R. 2759/S. 1362) and The Equitable Community Access to Pharmacist Services Act (H.R. 7213).

Client expense: $528,641 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Requested that CMS mandate state Medicaid programs to cover all PREP Act services (i.e., vaccination, testing, and treatment). Communication with the Center for Medicare and Medicaid Services regarding direct reimbursement under Medicare Program, annual payment updates, PBM transparency, and scope of practice. Communication with CMS, White House Offices, and Congressional Offices on Reimbursement through Medicare Part B. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House and Senate Offices, and HHS. Discussed telehealth reimbursement and virtual supervision flexibilities for pharmacist services with CMS. Discussed continuation of PREP Act allowances with HHS. Discussion with House and Senate Offices about the Pharmacist and Medically Underserved Areas Enhancement Act (H.R. 2759/S. 1362) and The Equitable Community Access to Pharmacist Services Act (H.R. 7213).

Client expense: $260,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Issues related to COVID medical response,; COVID-19 vaccine distribution,; and health disparities; S.1362 - Pharmacy and Medically Underserved Areas Enhancement Act; H.R. 7667, Food & Drug Amendments of 2022; S. 4348, the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Cures 2.0 - This bill is in discussion draft form. Lobbying on issues in bill related to medication adherence, caregiver training, pre-approval information exchange, cell and gene therapies, digital therapeutics, and confirmatory studies for accelerated approval drugs. H.R. 7008 - Pre-approval information exchange act of 2022 - lobbying for the introduction of a bill to codify FDA guidance creating a safe harbor for the practice of pre-approval information exchange between drug manufacturers and health plans. S.1909/HR. 3554 - A bill relating to direct and indirect remuneration in Medicare Part D. S. 1362 - Pharmacy and Medically Underserved Areas Enhancement Act - to provide for coverage under the Medicare program of pharmacist services S.2416 - NOVEL Act - A bill relating to the assignment of HCPCS codes and national coverage determinations for certain novel pharmaceutical products H.R. 7667 - PDUFA Reauthorization - lobbying for the inclusion of HR 7008 in HR 7667 and passage.

Client expense: $100,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 1868 - To prevent across-the-board direct spending cuts, and for other purposes. The bill continues to exempt Medicare from sequestration until December 31, 2021. Cures 2.0 - Lobbying on issues in bill related to medication adherence, caregiver training, pre-approval information exchange, cell and gene therapies, digital therapeutics, and confirmatory studies for accelerated approval drugs. Pre-approval information exchange - lobbying for the introduction of a bill to codify FDA guidance creating a safe harbor for the practice of pre-approval information exchange between drug manufacturers and health plans. S.1909/HR. 3554 - A bill relating to direct and indirect remuneration in Medicare Part D. S. 1362 - Pharmacy and Medically Underserved Areas Enhancement Act - to provide for coverage under the Medicare program of pharmacist services S.2416 - NOVEL Act - A bill relating to the assignment of HCPCS codes and national coverage determinations for certain novel pharmaceutical products

Client expense: $100,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 3554 / S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act; H.R. 2608, the Ensuring Seniors Access to Local Pharmacies Act; H.R. 2759 / S. 1362, the Pharmacy and Medically Underserved Areas Enhancement Act; H.R. 3682, the Improving Transparency to Lower Drug Costs Act; H.R. 2484, the Lowest Price for Patients Act; H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R. 19 / S. 2164, the Lower Costs, More Cures Act of 2021; H.R. 3173, the Improving Seniors Timely Access to Care Act of 2021; H.R. 4121, the PRO Seniors Act; Proposed inclusion of Medicaid managed care spread pricing prohibition to pay for H.R. 3684, the Infrastructure Investment and Jobs Act; H.R. 5237, the Reduced Costs and Continued Cures Act of 2021 H.R. 5376, the Build Back Better Act; H.R. 5804, the Expanding Access to Diabetes Self-Management Training Act of 2021; H.R. 6101, the Drug Price Transparency in Medicaid Act of 2021; Part B billing and COVID oral antivirals; S. 3700, the Affordable Insulin Now Act; H.R. 7213, Equitable Community Access to Pharmacist Services Act; CY 2023 Medicare Advantage and Part D Final Rule (CMS-4192-F); Draft legislation, the Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act; H.R. 5376, the Inflation Reduction Act of 2022

Client expense: $400,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Small Business Administration (SBA), White House Office

Issues pertaining to pharmacists' services including S 1362, Pharmacy and Medically Underserved Areas Enhancement Act and HR 7213, Equitable Community Access to Pharmacists Services Issues relating to the pharmaceutical supply chain, including HR 2870, Essential Medicines Strategic Stockpile Act Drug pricing legislation, including S 1388

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Drug Pricing HR 5376, Build Back Better Act HR 4385/S 3080, the Cancer Drug Parity Act HR 2759/S 1362, the Pharmacy and Medically Underserved Areas Enhancement Act HR 7213, the Equitable Community Access to Pharmacists Services Act Cancer Moonshot

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office

IPC supports The Pharmacy Benefit Manager Transparency Act of 2022 IPC supports S. 1909/H.R. 3554, the Pharmacy DIR Reform to Reduce Senior Drug Costs Act. Support regulations/laws that would eliminate pharmacy DIR. Medicare Program; Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs(CMS-4192-P). Support with amendments. IPC supports Pharmacists as Providers under Medicare Part B. IPC supports Pharmacy and Medically Underserved Areas Enhancement Act, H.R. 2759/S. 1362 IPC supports Pharmacists as Immunizers IPC supports 340B Program and contract pharmacies IPC supports Federal Retail Pharmacy COVID-19 Vaccination Program expansion. IPC supports MCO Medicaid reform and elimination of spread pricing IPC supports FTC investigation into vertical PBM arrangements IPC is against decreased pharmacy reimbursement in the TRICARE program IPC is neutral and sought clarifications on the drug pricing provisions of the Inflation Reduction Act of 2022.

Client expense: $30,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE, White House Office

H.R. 2759/S. 1362 -- the Pharmacy and Medically Underserved Areas Enhancement Act, legislation to recognize pharmacists and their services in Medicare Part B. H.R. 7213 -- This bill expands Medicare coverage to permanently include services provided by a pharmacist, including incidental services and supplies, related to testing, drug regimens, and vaccines for COVID-19, influenza, and certain other illnesses.

Client expense: $35,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 1868 - To prevent across-the-board direct spending cuts, and for other purposes. The bill continues to exempt Medicare from sequestration until December 31, 2021. Cures 2.0 - Lobbying on issues in bill related to medication adherence, caregiver training, pre-approval information exchange, cell and gene therapies, digital therapeutics, and confirmatory studies for accelerated approval drugs. Pre-approval information exchange - lobbying for the introduction of a bill to codify FDA guidance creating a safe harbor for the practice of pre-approval information exchange between drug manufacturers and health plans. S.1909/HR. 3554 - A bill relating to direct and indirect remuneration in Medicare Part D. S. 1362 - Pharmacy and Medically Underserved Areas Enhancement Act - to provide for coverage under the Medicare program of pharmacist services S.2416 - NOVEL Act - A bill relating to the assignment of HCPCS codes and national coverage determinations for certain novel pharmaceutical products

Client expense: $90,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Cures 2.0 - This bill is in discussion draft form. Lobbying on issues in bill related to medication adherence, caregiver training, pre-approval information exchange, cell and gene therapies, digital therapeutics, and confirmatory studies for accelerated approval drugs. H.R. 7008 - Pre-approval information exchange act of 2022 - lobbying for the introduction of a bill to codify FDA guidance creating a safe harbor for the practice of pre-approval information exchange between drug manufacturers and health plans. S.1909/HR. 3554 - A bill relating to direct and indirect remuneration in Medicare Part D. S. 1362 - Pharmacy and Medically Underserved Areas Enhancement Act - to provide for coverage under the Medicare program of pharmacist services S.2416 - NOVEL Act - A bill relating to the assignment of HCPCS codes and national coverage determinations for certain novel pharmaceutical products H.R. 7667 - PDUFA Reauthorization - lobbying for the inclusion of HR 7008 in HR 7667 and passage.

Client expense: $90,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Pharmacy provider status, retail pharmacy H.R.2759 and S.1362,; Pharmacy DIR Reform to Reduce Senior Drug Costs Act S.1909 and H.R.3554,; Drug pricing and transparency, access and adherence H.R.3 and H.R.19

Client expense: $340,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to COVID medical response,; COVID-19 vaccine distribution,; and health disparities; S.1362 - Pharmacy and Medically Underserved Areas Enhancement Act. COVID relief and pandemic response, pandemic preparedness,; Supply chain, global operations, trade,; Pharmacy provider status, retail pharmacy H.R.2759 and S.1362,;ARPA-H, clinical trials, healthcare innovation, CURES 2.0,; Social determinants of health, health disparities in underserved communities; chronic health conditions H.R.2503.

Client expense: $340,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to COVID medical response,; COVID-19 vaccine distribution,; and health disparities; S.1362 - Pharmacy and Medically Underserved Areas Enhancement Act; H.R. 7667, Food & Drug Amendments of 2022; S. 4348, the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Reimbursement for psychiatric pharmacists services under Medicare Part D; Continuation of telehealth waivers, including audio only services; H.R. 7213 - Equitable Community Access to Pharmacist Services Act; H.R. 3173/S. 3018 - Improving Seniors' Timely Access to Care Act; H.R. 4058/S. 2061 - Telemental Health Care Access Act; H.R. 2759/S. 1362 - Pharmacy and Medically Underserved Areas Enhancement Act.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Requested that CMS mandate state Medicaid programs to cover all PREP Act services (i.e., vaccination, testing, and treatment). Communication with the Center for Medicare and Medicaid Services regarding direct reimbursement under Medicare Program, annual payment updates, PBM transparency, and scope of practice. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect remuneration fees (DIR) under Medicare Part D and Medicare rebate reform. Communication with CMS, White House Offices, and Congressional Offices on Reimbursement through Medicare Part B. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House and Senate Offices, and HHS. Discussed telehealth reimbursement and virtual supervision flexibilities for pharmacist services with CMS. Discussed continuation of PREP Act allowances with HHS. Discussion with House and Senate Offices about the Pharmacist and Medically Underserved Areas Enhancement Act (H.R. 2759/S. 1362) and The Equitable Community Access to Pharmacist Services Act (H.R. 7213).

Client expense: $528,641 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 3554 / S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act; H.R. 2608, the Ensuring Seniors Access to Local Pharmacies Act; H.R. 2759 / S. 1362, the Pharmacy and Medically Underserved Areas Enhancement Act; H.R. 3682, the Improving Transparency to Lower Drug Costs Act; H.R. 2484, the Lowest Price for Patients Act; H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R. 19 / S. 2164, the Lower Costs, More Cures Act of 2021; H.R. 3173, the Improving Seniors Timely Access to Care Act of 2021; H.R. 4121, the PRO Seniors Act; Proposed inclusion of Medicaid managed care spread pricing prohibition to pay for H.R. 3684, the Infrastructure Investment and Jobs Act; H.R. 5237, the Reduced Costs and Continued Cures Act of 2021 H.R. 5376, the Build Back Better Act; H.R. 5804, the Expanding Access to Diabetes Self-Management Training Act of 2021; H.R. 6101, the Drug Price Transparency in Medicaid Act of 2021; Part B billing and COVID oral antivirals; S. 3700, the Affordable Insulin Now Act; H.R. 7213, Equitable Community Access to Pharmacist Services Act; CY 2023 Medicare Advantage and Part D Proposed Rule (CMS-4192-P); Draft legislation, the Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act

Client expense: $460,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Small Business Administration (SBA), White House Office

issues related to the practice of pharmacy S.1362 - 117th Congress (2021-2022)-Pharmacy and Medically Underserved Areas Enhancement Act H.R.7213 - 117th Congress (2021-2022)-Equitable Community Access to Pharmacist Services Act

Client expense: Not reported · Firm income: Not reported

Issues pertaining to pharmacists' services including S 1362, Pharmacy and Medically Underserved Areas Enhancement Act and HR 7213, Equitable Community Access to Pharmacists Services Issues relating to the pharmaceutical supply chain, stockpiling, and COVID vaccine distribution/drug shortage including HR 2870, Essential Medicines Strategic Stockpile Act Drug pricing legislation, including S 1388

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 2759/S. 1362 -- the Pharmacy and Medically Underserved Areas Enhancement Act, legislation to recognize pharmacists and their services in Medicare Part B. H.R. 7213 -- This bill expands Medicare coverage to permanently include services provided by a pharmacist, including incidental services and supplies, related to testing, drug regimens, and vaccines for COVID-19, influenza, and certain other illnesses.

Client expense: $35,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Drug Pricing HR 5376, Build Back Better Act HR 4385/S 3080, the Cancer Drug Parity Act HR 2759/S 1362, the Pharmacy and Medically Underserved Areas Enhancement Act HR 7213, the Equitable Community Access to Pharmacists Services Act Cancer Moonshot

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office

IPC supports The Pharmacy Benefit Manager Transparency Act of 2022 IPC supports S. 1909/H.R. 3554, the Pharmacy DIR Reform to Reduce Senior Drug Costs Act. Support regulations/laws that would eliminate pharmacy DIR. Medicare Program; Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs(CMS-4192-P). Support with amendments. IPC supports Pharmacists as Providers under Medicare Part B. IPC supports Pharmacy and Medically Underserved Areas Enhancement Act, H.R. 2759/S. 1362 IPC supports Pharmacists as Immunizers IPC supports 340B Program and contract pharmacies IPC supports Federal Retail Pharmacy COVID-19 Vaccination Program expansion. IPC supports MCO Medicaid reform and elimination of spread pricing IPC supports FTC investigation into vertical PBM arrangements

Client expense: $30,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE, White House Office

Pharmacy provider status, retail pharmacy H.R.2759 and S.1362,; Pharmacy DIR Reform to Reduce Senior Drug Costs Act S.1909 and H.R.3554,; Drug pricing and transparency, access and adherence H.R.3 and H.R.19

Client expense: $890,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to COVID medical response,; COVID-19 vaccine distribution,; and health disparities; S.1362 - Pharmacy and Medically Underserved Areas Enhancement Act. COVID relief and pandemic response, pandemic preparedness,; Supply chain, global operations, trade,; Pharmacy provider status, retail pharmacy H.R.2759 and S.1362,;ARPA-H, clinical trials, healthcare innovation, CURES 2.0,; Social determinants of health, health disparities in underserved communities; chronic health conditions H.R.2503.

Client expense: $890,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Pharmacy provider status, retail pharmacy H.R.2759 and S.1362,; Pharmacy DIR Reform to Reduce Senior Drug Costs Act S.1909 and H.R.3554,; Drug pricing and transparency, access and adherence H.R.3 and H.R.19

Client expense: $900,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to COVID medical response,; COVID-19 vaccine distribution,; and health disparities; S.1362 - Pharmacy and Medically Underserved Areas Enhancement Act. COVID relief and pandemic response, pandemic preparedness,; Supply chain, global operations, trade,; Pharmacy provider status, retail pharmacy H.R.2759 and S.1362,;ARPA-H, clinical trials, healthcare innovation, CURES 2.0,; Social determinants of health, health disparities in underserved communities; chronic health conditions H.R.2503.

Client expense: $900,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to COVID medical response,; COVID-19 vaccine distribution,; and health disparities; S.1362 - Pharmacy and Medically Underserved Areas Enhancement Act

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Drug Pricing HR 5376, Build Back Better Act HR 4385/S 3080, the Cancer Drug Parity Act HR 2759/S 1362, the Pharmacy and Medically Underserved Areas Enhancement Act

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Reimbursement for psychiatric pharmacists services under Medicare Part D; Continuation of telehealth waivers through 2021, including audio only services and payment parity with in-person care; H.R. 7213 - Equitable Community Access to Pharmacist Services Act; H.R. 3173/S. 3018 - Improving Seniors' Timely Access to Care Act; H.R. 4058/S. 2061 - Telemental Health Care Access Act; H.R. 2759/S. 1362 - Pharmacy and Medically Underserved Areas Enhancement Act.

Client expense: Not reported · Firm income: $20,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Communicate with the Center for Medicare and Medicaid Services regarding direct reimbursement under Medicare Program, annual payment updates, PBM transparency, and scope of practice. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect remuneration fees (DIR) under Medicare Part D and Medicare rebate reform. Communication with CMS, White House Offices, and Congressional Offices on Reimbursement through Medicare Part B. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House and Senate Offices, and HHS. Discussed telehealth reimbursement and virtual supervision flexibilities for pharmacist services with CMS. Discussed continuation of PREP Act allowances with HHS. Discussion with House and Senate Offices about the Pharmacist and Medically Underserved Areas Enhancement Act (H.R. 2759/S. 1362) and The Equitable Community Access to Pharmacist Services Act (H.R. 7213).

Client expense: $355,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Issues pertaining to pharmacists' services including S 1362, Pharmacy and Medically Underserved Areas Enhancement Act and HR 7213, Equitable Community Access to Pharmacists Services Issues relating to the pharmaceutical supply chain, stockpiling, and COVID vaccine distribution/drug shortage including HR 2870, Essential Medicines Strategic Stockpile Act Drug pricing legislation, including S 1388

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 3554 / S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act; H.R. 2608, the Ensuring Seniors Access to Local Pharmacies Act; H.R. 2759 / S. 1362, the Pharmacy and Medically Underserved Areas Enhancement Act; H.R. 3682, the Improving Transparency to Lower Drug Costs Act; H.R. 2484, the Lowest Price for Patients Act; H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R. 19 / S. 2164, the Lower Costs, More Cures Act of 2021; H.R. 3173, the Improving Seniors Timely Access to Care Act of 2021; H.R. 4121, the PRO Seniors Act; Proposed inclusion of Medicaid managed care spread pricing prohibition to pay for H.R. 3684, the Infrastructure Investment and Jobs Act; H.R. 5237, the Reduced Costs and Continued Cures Act of 2021 H.R. 5376, the Build Back Better Act; H.R. 5804, the Expanding Access to Diabetes Self-Management Training Act of 2021; H.R. 6101, the Drug Price Transparency in Medicaid Act of 2021; Part B billing and COVID oral antivirals; S. 3700, the Affordable Insulin Now Act; H.R. 7213, Equitable Community Access to Pharmacist Services Act; CY 2023 Medicare Advantage and Part D Proposed Rule (CMS-4192-P)

Client expense: $2,010,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Small Business Administration (SBA), White House Office

IPC supports S. 1909/H.R. 3554, the Pharmacy DIR Reform to Reduce Senior Drug Costs Act. Support regulations/laws that would eliminate pharmacy DIR. Medicare Program; Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs(CMS-4192-P). Support with amendments. IPC supports Pharmacists as Providers under Medicare Part B. IPC supports Pharmacy and Medically Underserved Areas Enhancement Act, H.R. 2759/S. 1362 IPC supports Pharmacists as Immunizers IPC supports 340B Program and contract pharmacies IPC supports Federal Retail Pharmacy COVID-19 Vaccination Program expansion. IPC supports MCO Medicaid reform and elimination of spread pricing

Client expense: $30,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE, White House Office

Cures 2.0 - This bill is in discussion draft form. Lobbying on issues in bill related to medication adherence, caregiver training, pre-approval information exchange, cell and gene therapies, digital therapeutics, and confirmatory studies for accelerated approval drugs. Pre-approval information exchange - lobbying for the introduction of a bill to codify FDA guidance creating a safe harbor for the practice of pre-approval information exchange between drug manufacturers and health plans. S.1909/HR. 3554 - A bill relating to direct and indirect remuneration in Medicare Part D. S. 1362 - Pharmacy and Medically Underserved Areas Enhancement Act - to provide for coverage under the Medicare program of pharmacist services S.2416 - NOVEL Act - A bill relating to the assignment of HCPCS codes and national coverage determinations for certain novel pharmaceutical products

Client expense: $110,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE